Focus: IBSA is a mid-sized Swiss pharmaceutical company founded in 1945 that specializes in treatments and nutraceuticals across neurology and gastroenterology. With 1,001–5,000 employees, it operates as a regional specialty player with heavy dependence on a single flagship product.
Profile data last refreshed 18h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow IBSA Institut Biochimique to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for IBSA Institut Biochimique
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from IBSA Institut Biochimique's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship product generating 78% of company revenue with extended exclusivity to 2035; core pain franchise pillar.
Secondary diclofenac formulation approaching loss of exclusivity; represents erosion risk to overall pain portfolio.
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo